Pillay D - Search Results

1

Implications of HIV drug resistance on first- and second-line therapies in resource-limited settings: report from a workshop organized by the Collaborative HIV and Anti-HIV Drug Resistance Network.

Pillay D, Albert J, Bertagnolio S, Boucher C, Brun-Vezinet F, Clotet B, Giaquinto C, Perno CF. Pillay D, et al. Antivir Ther. 2013;18(6):831-6. doi: 10.3851/IMP2650. Epub 2013 Jun 5. Antivir Ther. 2013. PMID: 23740717

2

HIV viral load: the myth of the undetectable?

Pillay D. Pillay D. Rev Med Virol. 2002 Nov-Dec;12(6):391-6. doi: 10.1002/rmv.373. Rev Med Virol. 2002. PMID: 12410530 Review.

3

Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).

Gibb DM, Walker AS, Kaye S, De Rossi A, Ait-Khaled M, Pillay D, Muñoz-Fernandez MA, Loveday C, Compagnucci A, Dunn DT, Babiker AG. Gibb DM, et al. Among authors: pillay d. Antivir Ther. 2002 Dec;7(4):293-303. Antivir Ther. 2002. PMID: 12553485 Clinical Trial.

4

Identification of a transmission chain of HIV type 1 containing drug resistance-associated mutations.

Taylor S, Cane P, Hué S, Xu L, Wrin T, Lie Y, Hellmann N, Petropoulos C, Workman J, Ratcliffe D, Choudhury B, Pillay D. Taylor S, et al. Among authors: pillay d. AIDS Res Hum Retroviruses. 2003 May;19(5):353-61. doi: 10.1089/088922203765551700. AIDS Res Hum Retroviruses. 2003. PMID: 12803994

5

Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients.

Sabin CA, Wilkins E, Murphy M, Fisher M, de Ruiter A, Easterbrook PJ, Leen C, Vlahakis E, Cane PA, Li X, Pillay D; UK Expanded Access Amprenavir Programme. Sabin CA, et al. Among authors: pillay d. Antivir Ther. 2003 Aug;8(4):301-8. Antivir Ther. 2003. PMID: 14518699

6

Drug-resistant HIV-1 in the semen of men receiving antiretroviral therapy with acute sexually transmitted infections.

Taylor S, Sadiq ST, Weller I, Kaye S, Workman J, Cane PA, Bennett J, Copas AJ, Drake SM, Pillay D. Taylor S, et al. Among authors: pillay d. Antivir Ther. 2003 Oct;8(5):479-83. Antivir Ther. 2003. PMID: 14640396

7

Drug resistance mutations in HIV-1.

Johnson VA, Brun-Vézinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DD; International AIDS Society-USA Drug Resistance Mutations Group. Johnson VA, et al. Among authors: d aquila rt, pillay d. Top HIV Med. 2003 Nov-Dec;11(6):215-21. Top HIV Med. 2003. PMID: 14724329 Review.

8

Transmission of HIV-1 drug resistance.

Tang JW, Pillay D. Tang JW, et al. Among authors: pillay d. J Clin Virol. 2004 May;30(1):1-10. doi: 10.1016/j.jcv.2003.12.002. J Clin Virol. 2004. PMID: 15072747 Review.

9

HIV-1 pol gene variation is sufficient for reconstruction of transmissions in the era of antiretroviral therapy.

Hué S, Clewley JP, Cane PA, Pillay D. Hué S, et al. Among authors: pillay d. AIDS. 2004 Mar 26;18(5):719-28. doi: 10.1097/00002030-200403260-00002. AIDS. 2004. PMID: 15075506

10

Clinically validated genotype analysis: guiding principles and statistical concerns.

Brun-Vézinet F, Costagliola D, Khaled MA, Calvez V, Clavel F, Clotet B, Haubrich R, Kempf D, King M, Kuritzkes D, Lanier R, Miller M, Miller V, Phillips A, Pillay D, Schapiro J, Scott J, Shafer R, Zazzi M, Zolopa A, DeGruttola V. Brun-Vézinet F, et al. Among authors: pillay d. Antivir Ther. 2004 Aug;9(4):465-78. Antivir Ther. 2004. PMID: 15456077 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

737 results

Search Page

Filters